70 results about "Million Units" patented technology

The invention provides a blocking buffer for encapsulated plate, which consists of 0.5 to 10g/L of protein substances, 0.5 to 5g/L of sugar substances, 0.5 to 10g/L of amino acid substances, 0.2 to 2g/L of surfactant, 50 to 5 million unit/L of gentamicin sulphate, 0.2 to 2g/L of Proclin 300 and 0.02mol/L of phosphate buffer with the pH of 7.4. The encapsulated plate using the blocking buffer of the invention can not only block off biological active substances, but can also maintain the activity of the biological active substances for a longer time when the encapsulated plate departs from low temperature environment, thus the problem in relevant technology that the encapsulated plate is liable to lose activity when departing from lower temperature storage environment can be settled. In addition, the blocking buffer of the invention is easy in formulation, free from the impact on sensitivity, low in cost and simple in operation and has no environmental pollution and no toxicity and harm to human body.

The invention provides a novel process for producing sodium heparin, which comprises the following steps of enzymolysis, gum exchange adsorption, resin washing, heparin eluting, alcohol precipitation,precipitation once more, dehydration drying, crushing, mixing and packaging. The process has mature flow, convenient operation, no emission of waste intestinal dregs and overproof wastewater, complete enzymolysis reaction, short reaction time of 30 hours, low production energy consumption, low reaction temperature of between 70 and 80 DEG C, heparin extracting ratio over 90 percent, high unit yield of the heparin, only need of 1,700 pieces of small intestines of pigs for each 100 million units of heparin, low production cost, increase of economic benefit over 30 percent per 100 million units,no emission of dirty intestinal dregs and overproof wastewater, and suitability for large-scale production.

The invention discloses a biological cell freezing antifreeze, and 100ml of the cell freezing antifreeze consists of the following raw materials: 0.025 to 0.3g of kelp polysaccharide, 2.0 to 3.5g of glucose, 0.5 to 1.5g of sodium citrate, 60 to 80ml of distilled water, 10 to 20ml of albumin, 5 to 18ml of glycerol and 0.05 to 0.15 million units of penicillin. The preparation method is that: the glucose and the sodium citrate are dissolved in the distilled water to prepare a base liquid; the albumin is added, the mixture is mixed evenly, and the penicillin is added to prepare a I liquid; the glycerol is added in the I liquid to prepare a II liquid; the kelp polysaccharide is added in the II liquid for even mixing; the pH value is adjusted to 6 to 7.5, then the filtration and sterilization are carried out, and the mixture is cooled until reaching the room temperature and then arranged in a refrigerator of 2 to 5 DEG C for standby. The cell freezing antifreeze is applicable to the cryopreservation of mammalian semen, somatic cells, oocytes, early embryos, organs and tissues, in particular to the cryopreservation of the semen of various mammals.

This invention discloses a method for manufacturing pineapple proteinase freeze-dried powders, which can solve the problem of low activity faced by conventional pineapple proteinase. The method comprises the steps of: washing pineapple stems with water, pressing to obtain juice, filtering, adsorbing the filtrate with zinc oxide, desorbing, ultrafiltering, concentrating and freeze-drying to obtain pineapple proteinase freeze-dried powders, whose enzyme activity can reach 600 million units per gram.

The invention discloses a fat-soluble vitamin nano microemulsion oral liquid which comprises 2-4g of vegetable oil, 4-6g of vitamin E acetate, 3-3.6 million units of vitamin D3, 2-4g of vitamin K3, 8-12ml of Tween-80, 3-5g of RH 40, 5-7g of AEO-9 (fatty alcohol-polyoxyethylene ether-9), 0.3-0.7g of folic acid, 13-17g of calcium pantothenate, 1-2g of antioxidant, 0.8-1.4g of vitamin C, 8-11 million units of vitamin A, 32-36g of nicotinamide, 2.5-4.5g of vitamin B2, 8-12g of glycine, 1.8-2.4g of vitamin B1, 40-80mg of biotin, 0.8-1.2g of vitamin B6 and 8-12mg of vitamin B12. The invention also discloses a preparation method of the fat-soluble vitamin nano microemulsion oral liquid.

The invention belongs to the technical field of veterinary medicine, specifically to an injection for preventing and treating porcine viral diseases and a preparation method thereof. Every 1000ml of the injection contains 1 to 100g of thymopoietin, 1 to 10*10 <8> IU of interferon, 10 to 50 million units of gentamycin sulfate, 0.1 to 2g of antioxidant, 0.2 to 0.4g of protective agent, 50 to 100ml of buffer, 20 to 80ml of osmotic pressure adjusting agent, a pH adjusting agent and the balance of water for injection. The preparation in the invention is wide in application, fast in curative effect, little in medicine dosage, low in cost, and difficult to bring germ contamination. The injection reduces the stress reaction caused by capturing the animal for many times in injecting, and overcomes the shortcoming that the water needle made of thymopoietin and interferon is unstable.

The invention belongs to the field of animal pharmaceutical preparations, and relates to a compound gentamicin sulphat in-situ gel preparation for injection and a preparation method thereof. The in-situ gel preparation disclosed by the invention comprises the following components in parts by weight: 9.0 parts of gentamicin (9 million units), 6.0 parts of TMP (Trimethoprim), 15.5-30.5 parts of P407, 0.5-10.5 parts of P188, 30.0-90.5 parts of water, 0.01-10.0 parts of polymer blocker, 5.0-45.0 parts of solubilising stabilizer, 0.01-3.0 parts of preservative, 0.01-5.0 parts of antioxygen and a proper amount of pH adjustor. The in-situ gel preparation disclosed by the invention is freely moveable liquid at room temperature and forms semi-solid gel after drug delivery through intramuscular injection or subcutaneous injection; drug delivery is only carried out once during a treatment course; the in-situ gel preparation has the advantages of steady property, long drug delivery duration, exact curative effect, strong animal adaptation, no toxic and side effects and adverse reaction and the like, and is simple to operate and convenient for drug delivery; the in-situ gel preparation disclosed by the invention has broad-spectrum antibacterial activity and can be used as a medicine for preventing and treating diseases of pigs, sheep, dogs, cats, cattle and the like.

A drug for treating rhinitis and a preparation method thereof relate to an improved drug for treating the rhinitis. The invention provides the drug for treating the rhinitis and the preparation method thereof. The drug contains 1.6 million units of penicillin sodium salt, 6-9mg of hydrocortisone and 4-7mg of dexamethasone sodium phosphate according to weight proportion. The preparation method is characterized by comprising the following steps: (1) 0.8 million units of the penicillin sodium salt and 6-9mg of the hydrocortisone are mixed and dissolved; (2) 0.8 million units of the penicillin sodium salt and 4-7mg of the dexamethasone sodium phosphate are mixed and dissolved; and (3) the two mixed solutions are mixed to prepare the drug for treating the rhinitis.

The invention provides an aprotinin freeze-dried powder injection and a preparation method thereof. The freeze-dried powder injection is composed of the following substances: 28-556 million units of aprotinin, 10-20g arginine, 5-20g human serum albumin, and 100g mannitol. In aprotinin freeze-dried powder injection production process of the present invention, rginine and human serum albumin are selected to be excipients which mainly play the roles of protecting the active ingredient aprotinin; and mannitol is selected to be a freeze-drying excipient to enable the shape-forming by freeze drying. A 5% phosphoric acid solution or a 5% sodium phosphate solution is selected as a pH adjusting agent which enables the pH of a prepared liquid medicine to be maintained consistent with the pH of the liquid medicine which is redissolved after the powder is freeze dried, so that the product quality is more stable. According to the invention, an improved freeze-drying process is adopted, thus shortening the freeze-drying time and helping to improve product quality and save energy and reduce cost.

The invention discloses a Japanese bigleaf magnolia leaf cutting propagation method, which comprises the following steps: (1) preparation of cutting matrix and rooting agent solution, namely mixing perlite, vermiculite and yellow sand to prepare the cutting matrix, and adding the following raw materials by weight per 1kg: 50-200mg of vitamin C, 50-200mg of vitamin B2, 50-200mg of vitamin B6, 80-160 million units of gentamicin, 200-300mg of naphthalene acetic acid, and 200-300mg of indolebutyric acid, to prepare a rooting agent solution; (2) cutting propagation of leaves, namely shearing Japanese bigleaf magnolia leaves and soaking into the rooting agent solution, washing with clear water, and inserting the leaves into the cutting matrix; (3) fertilizer spraying of the leaves, namely spraying a rooting accelerator into the leaves once a week; and (4) transplanting, namely when new buds grow from leaves and at least two leaves grow, transplanting into a field. The Japanese bigleaf magnolia leaf cutting propagation method is short in propagation period, fast in growth propagation, and few in propagation materials, and has the time-saving and effort-saving effects.

The present invention relates to a composition capable of reducing piglet irritability. Each kg of the composition contains, 1-4 million units of warm amylase, 5-50 million units of neutral protease, 10-80 million units of pectinase, 60-60000 million units of xylanase, 50-6000 million units of cellulase, and 10-200g of oligosaccharide.

The invention discloses a medicament for the treatment of fruit tree silver leaf, wherein the formulation of the medicament includes 72% streptomycin sulfate (10 million units) 3-4%, kanamycin sulphate (5 million units) 5-8%, 4% kasugamycin 11-14%, 20% Validamycin (5 million units) 25-30%, water 30%, nutrient solution 2116 2%, leftover bits and pieces of gourmet 18%.

The invention discloses a chemiluminescent substrate solution and a procalcitonin detection kit utilizing the same. The chemiluminescent substrate solution is prepared from 0.8-1.5 g/L of luminol or its derivatives, 0.05-0.6 g/L2 of amino-4-nitro phenol, 0.01-0.05 mg/L of 9,9-dihexyl-2,7-dibromofluorene, 3-6 g/L of polyvinyl alcohol, 6-20 g/L of polyvinylpyrrolidone, 3-4.5 g/L of polyethylene glycol 600, 100-300 million units/L of gentamycin sulfate, 0.1-1.0 g/L of carbamide peroxide and 0.1 mol/L of a Tris-HCl buffer solution with the pH of 9.0. The chemiluminescent substrate solution is a single solution, can not only achieve the HRP enzyme catalyzed chemiluminescence reaction and can also effectively improve the luminous intensity and decrease a luminous background to achieve high-sensitivity detection.

The invention discloses an oral milk coagulant for treating infant thrush. The oral milk coagulant is prepared from the following components by weight: 150 million units of 10-20 million/ml nystatin, 8ml of medical 5% sodium bicarbonate, 0.5g of vitamin C, 250mg of vitamin B, 2ml of cod-liver oil, 10ml of liquid pectin, 1g of lactose and 0-0.2ml of traditional Chinese medicine extract. Compared with the prior art, the oral milk coagulant has the effects of simpleness in use, easiness for coating, lasting pasting effect of medicines at an infected part, long action time, rapid effect and high bioavailability; by adopting the oral milk coagulant, the problems of unprofessional operation of family numbers of patients in drug separation, waste of traditional Chinese medicines during a drug blending process and difficulty in drug application; clinical trials prove that the oral milk coagulant disclosed by the invention has a significant effect in treating infant thrush and has no toxic and side effects through the selection of proper components in proper proportion.

The invention discloses an edge-rolling occluding cutter forming process which totally comprises four steps each of which is finished by a matched forming cutter. The forming process specifically comprises the following steps of: 1, bending the flange at the end cover of a dish-washing machine liner for 45 degrees; 2, rolling the flanges of the end cover of the dish-washing machine liner and the cylindrical body of the dish-washing machine liner into a whole body in a vertical state; 3, rolling the vertical edges which are rolled into a whole body to form a 45-degree inclined angle, thereby being beneficial to the final forming; and 4, compacting the flanges to finally finish the occluding forming step. The edge-rolling occluding cutter forming process is characterized in that the straight face of the edge of the third forming cutter used in the step 3 in the forming process is an inclined plane having an angle of 3-45 degrees with a vertical line. The forming process has the beneficial effects that the percent of pass of liner products of dish-washing machines reaches 100%; and in economic benefit, given that the dish-washing machine yield of one dish-washing machine manufacturerin China is 1 million units per year at present and the defective rate is reduced by 3% by adoption of the forming process provided by the invention, 30 thousand units of defective products can be reduced for one manufacturer every year because of the adoption of the new process, and the economic loss is reduced by 9 million yuan per year if the cost of one unit is 300 yuan.

The invention discloses a protease of Momordica grosvenori Swingle as well as its extract method, which is prepared by: with fresh fruit, extracting juice, filtering, ultrafiltrating or salting-out chromatography, depositing with organic solvent, vacuum freezing or spray drying, and obtaining the coarse powder; dissolving the powder with distilled water for column chromatography, dialyzing to desalt, freeze drying, and obtaining the objective product. This product has strong hydrolytic activation to casein; the activity of coarse enzyme can achieve 1.5 million units/g and about two times to coarse papain. This invention adds one plant protease resource, makes our rotease resource do not depend on only pawpaw and pineapple, and has important meaning to enzymology research, protease food development, and other opposite fields.

The invention relates to a method for preparing polymyxin B sulfate for injection. The auxiliary material of the prepared polymyxin B sulfate for injection is injection water only, and the specification of the polymyxin B sulfate for injection is 0.5 million units. The polymyxin B sulfate for injection, prepared through the method, has significantly improved quality and stability, and has significantly reduced insoluble particle quantity.

The invention relates to the technical field of deep processing of agricultural and sideline products, and specifically relates to a heparin sodium extracting method. The heparin sodium extracting method comprises the following steps: performing first enzymolysis under the salinity of 4.0-4.5 degrees and the temperature of 38+/-2 DEG C; then performing secondary enzymolysis under the salinity of 3.0-3.5 degrees and the temperature of 55+/-1 DEG C; and then sequentially carrying out protein denaturation, absorbing, washing, eluting, dewatering and desalting, and drying after the two enzymolysis. According to the heparin sodium extracting method, the temperature of 38+/-2 DEG C and the salinity of 4.0-4.5 degrees are creatively selected for the first enzymolysis, and the temperature of 55+/-1 DEG C and the salinity of 3.0-3.5 degrees are selected for the second enzymolysis, so that the heparin sodium yield reaches 1490-1510 items per hundred million units; compared with a traditional first enzymolysis method and a secondary enzymolysis method disclosed in the prior art, the heparin sodium extracting method has the advantages that the enzymolysis dissociation recovering rate is increased, so that the heparin sodium yield is increased.

The invention relates to ulinastatin injection and a preparation method for the same. A formula of every 1,000 tubes of ulinastatin injection comprises 2,500 to 10,000 million units of ulinastatin, 1 to 30 grams of mannitol, 0 to 10 grams of sodium chloride, 0 to 5 grams of sodium hydrogen phosphate, 0 to 5 grams of monosodium phosphate and water for injection. The preparation method for the ulinastatin injection comprises the following steps of preparing an auxiliary solution of 2 to 4 DEG C, adding 1 to 5 grams of activated carbon with an average particle size of 6 to 9 microns to perform low-temperature adsorption treatment on the prepared auxiliary solution for 12 to 20 minutes at 2 to 4 DEG C, and dissolving ulinastatin with the treated auxiliary solution. The ulinastatin injection prepared by the preparation method according to the formula is relatively lower in adverse reaction rate and relatively higher in stability.

The invention discloses a preparation method for producing heparin sodium by animal small intestines. The preparation method is characterized in that the preparation of the heparin sodium is completed through steps of intestinal mucosa preparation, enzymolysis, adsorption, elution, sedimentation and desalination and drying. The preparation method disclosed by the invention has the advantages that the yield of the heparin sodium is effectively increased by reasonably regulating the preparation method, and the loss of activity of the heparin sodium is reduced; the prepared heparin sodium is more stable in quality; only 1400 to 1500 animal small intestines are needed by producing 100 million units of heparin sodium by adopting the preparation method disclosed by the invention, so that the production cost is greatly reduced.